Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial

Inhaled glucocorticosteroids (ICS) are the mainstay of treatment in asthma. Fluticasone furoate (FF) is a novel, once‐daily ICS asthma therapy. This study investigated the efficacy and safety of FF 50 mcg in patients with mild‐to‐moderate persistent asthma.

[1]  A. Woodcock,et al.  Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trial. , 2014, Respiratory medicine.

[2]  A. Woodcock,et al.  Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma , 2013, European Respiratory Journal.

[3]  A. Woodcock,et al.  Efficacy and safety of once-daily (OD) fluticasone furoate (FF) 50mcg over 24 weeks in adults and adolescents with persistent asthma , 2013 .

[4]  A. Woodcock,et al.  Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. , 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[5]  A. Woodcock,et al.  Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. , 2012, Respiratory medicine.

[6]  P. Demoly,et al.  Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years , 2012, European Respiratory Review.

[7]  I. Adcock,et al.  Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. , 2011, European journal of pharmacology.

[8]  A. Woodcock,et al.  Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial , 2011, Thorax.

[9]  A. Woodcock,et al.  Fluticasone Furoate (FF), A Once-Daily Inhaled Corticosteroid (ICS), Is Efficacious In Patients With Uncontrolled Asthma Across A Range Of Treatment Steps , 2011, ATS 2011.

[10]  E. Brink,et al.  The influence of personality traits and beliefs about medicines on adherence to asthma treatment. , 2011, Primary care respiratory journal : journal of the General Practice Airways Group.

[11]  R. Dahl,et al.  A 24-week comparison of low-dose ciclesonide and fluticasone propionate in mild to moderate asthma. , 2010, Respiratory medicine.

[12]  D. Price,et al.  Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study , 2010, BMC pulmonary medicine.

[13]  Mark Kosinski,et al.  The minimally important difference of the Asthma Control Test. , 2009, The Journal of allergy and clinical immunology.

[14]  L. Boulet,et al.  Benefits of low-dose inhaled fluticasone on airway response and inflammation in mild asthma. , 2009, Respiratory medicine.

[15]  I. McLay,et al.  X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. , 2008, Journal of medicinal chemistry.

[16]  A. Aggarwal,et al.  The relationship between FEV1 and peak expiratory flow in patients with airways obstruction is poor. , 2006, Chest.

[17]  J. Guest,et al.  Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs. , 2005, Primary care respiratory journal : journal of the General Practice Airways Group.

[18]  E. A. Kelly,et al.  Inflammatory changes associated with circadian variation in pulmonary function in subjects with mild asthma , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[19]  M. Weatherall,et al.  The relationship between FEV1 and PEF in the assessment of the severity of airways obstruction , 2002, Respirology.

[20]  J. R. Scotti,et al.  Available From , 1973 .

[21]  R Horne,et al.  Compliance in asthma. , 1999, Respiratory medicine.

[22]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[23]  G H Guyatt,et al.  Determining a minimal important change in a disease-specific Quality of Life Questionnaire. , 1994, Journal of clinical epidemiology.

[24]  G. Biasini.  [Drug therapy of asthma]. , 1977, Minerva pediatrica.